Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma ...

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic...

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a ...

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic ...

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinica...

Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will...

Read more

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treate...

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Read more

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT...

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!

Read more

EHA Award winners put in the spotlight in Copenhagen

Copenhagen, June 9 2016. At the 21st Congress of the European Hematology Association (EHA) in Copenhagen, in total thirteen hematology researchers will be awarded for their work. Research is the engine that drives improvements in patient care which is why EHA is keen in investing in Awards and Grants to stimulate and support hematology research.

 


Read more